A distinct inflammatory profile marked by neutrophil activity and cytokine elevation may underline poor biological response ...

The Lancet on the anti-IL-5 antibody mepolizumab in individuals with allergic asthma, evidence has accumulated that the pathogenetic role of eosinophils is fundamentally different between asthma ...

GlaxoSmithKline’s Nucala (mepolizumab) has gained a new FDA approval for the rare autoimmune disease eosinophilic granulomatosis with polyangiitis (EGPA). Nucala, an interleukin-5 (IL-5 ...

If approved for marketing, it would be a companion and successor to Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma and various other indications that made sales of ...

Results Of 190 participants included in the analysis, 153 (80%) had a positive response to mepolizumab [mean age at enrolment of 52±13 years, (59) 31% males]. Patients with positive mepolizumab ...

Ultimately, the profile of the best candidate for mepolizumab is still unclear. Several real-life reports suggest that mepolizumab at the dose of 100 mg/4 weeks, approved for eosinophilic ...

Medical news, education and information for physicians and health care professionals, presented by specialty and topic. From Healio and the Wyanoke Group.

Mepolizumab, which has also been studied for other diseases such as COPD, hypereosinophilic syndrome, chronic rhinosinusitis with nasal polyps and eosinophilic esophagitis, 37 is effective in reducing ...

Introduction: Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a rare necrotizing vasculitis characterized by eosinophilic inflammation that was traditionally treated with corticosteroids ...